Two poster presentations and an oral scientific presentation on the AERx insulin Diabetes Management System (iDMS) are being made by Novo Nordisk during the six-day 18th International Diabetes Federation Congress that opened yesterday in Paris, France. The AERx iDMS is an inhaled insulin system that is being developed by Aradigm Corporation (Nasdaq: ARDM - News) in conjunction with its partner Novo Nordisk.
The IDF Congress is a leading worldwide diabetes scientific forum created to discuss the global impact of diabetes, trends and related medical breakthroughs. This year's meeting is scheduled to attract more than 14,000 pharmaceutical and biotechnology representatives, as well as members of academia and the medical community.
Monday, 25th August 2003 11:30 AM
"Inhaled insulin via AERx(R) iDMS: no short-term effect on lung
function."
Wolmer, P., Bellaire, S., and Clauson, P.
Poster Display Session: Insulin Therapy
Poster #2203
Tuesday, 26th August 2003 11:30 AM
"Physicians' reaction to inhaled insulin, a new insulin delivery system."
Luery, D., and Chayer, D.
Poster Display Session: Insulin Therapy
Poster #2204
Thursday, 28th August 2003 1:30 PM
"Inhaled insulin treatment compliance by 46 patients using AERx(R) iDMS
Insulin Diabetes Management System".
Clauson, P., Okikawa, J., and Cramer, J.
Oral Session: OP 16 Devices
Presentation #126
biz.yahoo.com |
